China’s Biotech Drug Industry Outpaces Rest Of Asia
This article was originally published in PharmAsia News
The biotech drug industry in China has been growing by about 30 percent a year for the past two years, thanks to Chinese government efforts, industry experts say. They cite government support such as changes in regulation favorable to biopharmaceutical development. With that and its large patient population available for clinical trials, the country has become the fastest-growing in Asia in that sector, with the industry registering a 45 percent growth in sales last year. (Click here for more
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.